MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Ion Channels
Parents
*Key Terms: Biotechnology
BioTechnology
Children
*Advancing a novel class of highly selective small molecule inhibitors targeting NaV1.7, NaV1.8, and other voltage-gated ion channels to treat sensory hyperexcitability disorders such as chronic cough, itch, and pain
*Antibody-like therapeutics to solve ion channel and GPCR-driven diseases.
*Clinical-stage biopharmaceutical company focused on developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders.
*Developing selective ion channel modulators for the treatment of pain, cough, and other conditions
*Its technologies are used in DNA sequencing, diagnostics, drug development, biomolecular interaction, ion channel screening, and defense applications.
*Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease
*The company has built a core platform, which is called Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies
2021: A New Approach to Study Mechanically Activated Ion Channels_RePORT 〉 RePORTER
2021: NASEM Panel_DRUG RESEARCH AND DEVELOPMENT FOR ADULTS ACROSS THE OLDER AGE SPAN
2022: NIH_Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
2024: SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-opioid Treatments for Pain
2024: These microscopic tunnels are a goldmine for new medicines_Ion channel research
2025: How AI is Cracking Medicine’s Most Challenging Drug Targets
Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Epilepsy & Seizure
Consolidators: Quantum Computing
Developed a unique library of ion channel compounds for treating pain.
Develops novel drugs to treat pain, inflammation and cardiovascular disease using its expertise in novel ion channels and molecu
DHA_Industry Day 2019_Key_Note_Speaker_Brief
Focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets.
Funding: Federal R&D (Research and Development)_NOFO_PAR, PA, PAS, RFA, RFP, Grant, BAA, Cooperative Agreements (CAs)
Ion Channel Innovations
Permanently Charged Ion Channel Blockers as Anti-Inflammatory and Asthma Therapeutic Agents-Children's Hospital Boston
Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels.
Jumps
GPCRs (G protein-coupled receptors)